-

Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength

Following an increase of almost 10% a year ago

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.48 per share, an almost 7% increase from the previous dividend amount, bringing the new annualized dividend to $1.92 per share. The payment date is November 13, 2025, to stockholders of record as of October 23, 2025.

Stephan B. Tanda, Aptar President and CEO, commented, “Given the strength of our business outlook, the sustained long-term growth we anticipate from our Pharma segment, and our continued strong performance across all key financial metrics, the Board of Directors has approved an increase in the quarterly dividend. Since 2020, we’ve returned over $1 billion to shareholders through dividends and share repurchases, and we remain on track to achieve our 32nd consecutive year of increasing our total annual dividend.”

As previously announced, Aptar will hold its biennial Investor Day on Tuesday, September 9, 2025. The event will begin at 9:00 a.m. EDT. Presentations by members of executive management followed by a moderated Q&A session are expected to conclude at approximately 12:00 p.m. EDT. The general public can access the event and listen live by registering for the webcast.

About Aptar

Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

This press release contains forward-looking statements, including regarding our annualized dividends. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
+1 347-351-6407

Media Contact:
Katie Reardon
katie.reardon@aptar.com
+1 815-479-5671

AptarGroup, Inc.

NYSE:ATR

Release Summary
Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength
Release Versions

Contacts

Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
+1 347-351-6407

Media Contact:
Katie Reardon
katie.reardon@aptar.com
+1 815-479-5671

More News From AptarGroup, Inc.

Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray

CRYSTAL LAKE, Ill,--(BUSINESS WIRE)--Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray...

Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces Gael Touya as its Next President and Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year...

Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma’s Intranasal Delivery System Used in Phase II Clinical Study Investigational SPONTAN® Nasal Spray...
Back to Newsroom